Verona Pharma plc

VRNA

Held by 10 specialist biotech funds

High Convergence

10 funds opened new positions. Next phase2 readout (Ensifentrine): Dec 2026.

BiotechnologyCEO: David S. ZaccardelliIPO: 2017Website ↗

Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.

Recent News & Research

PubMed

Post-marketing safety of ensifentrine in COPD: A retrospective pharmacovigilance study using disproportionality analysis of FAERS/AEMS reports.

# Investment Summary: Verona Pharma Ensifentrine Safety Profile **Key Finding:** This retrospective pharmacovigilance analysis of post-market safety data for ensifentrine in COPD patients appears to have identified the drug's real-world adverse event profile through FAERS/AEMS reporting databases, which is critical for assessing commercial viability and regulatory standing. **Why It Matters for Investors:** Safety signals detected in post-market surveillance can significantly impact market adoption, label restrictions, or regulatory action—directly affecting peak sales projections and market exclusivity value. The timing and magnitude of any disproportionality signals relative to competitor therapies (dual bronchodilators like umeclidinium/vilanterol) will determine whether ensifentrine maintains its competitive positioning or faces commercial headwinds in a crowded COPD market. **Bottom Line:** Investors should monitor whether this analysis reveals

Sep 25, 2026

PubMed

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having 'bifunctional' bronchodilator and anti-inflammatory activity.

# Verona Pharma Investment Summary Ensifentrine, Verona's lead asset, represents a dual PDE3/4 inhibitor with a differentiated mechanism combining bronchodilation and anti-inflammatory effects in a single molecule—potentially addressing multiple disease pathways in COPD and asthma more efficiently than existing monotherapy approaches. The dual mechanism may provide clinical advantages in efficacy or dosing convenience, though commercial success will depend on Phase 3 trial outcomes and competitive positioning against established therapies and other PDE4 inhibitors already in clinical development. Investors should monitor upcoming trial data readouts and regulatory feedback to assess whether the bifunctional profile translates to meaningful clinical benefits that justify premium pricing in crowded respiratory markets.

Jul 5, 2026

Verona Pharma plc

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research